Literature DB >> 19765808

VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion.

Feng-qiang Wang1, Elaine Barfield, Sonia Dutta, Tarah Pua, David A Fishman.   

Abstract

BACKGROUND: The VEGF-VEGF receptor (VEGFR) signaling axis has emerged as a promising target for cancer therapy, attributing to its vital role in tumor angiogenesis and growth. We have previously reported the regulation of epithelial ovarian cancer (EOC) invasion and migration by VEGF and the implication of VEGF-VEGFR-2 axis in lysophosphatidic acid (LPA)-induced EOC invasion. However, the expression profile of VEGF and VEGFRs in EOC, their association with tumor aggressiveness, and their regulation by LPA remain unclear. OBJECTIVES AND METHODS: In this study, we examined the expression of VEGFR-1, VEGFR-2, neuropilin-1 (NRP-1), NRP-2, VEGF(121), and VEGF(165) in established EOC cell lines and assessed their correlation with cell invasiveness. Moreover, using an ovarian cancer tissue qPCR array, we analyzed VEGFR-2 expression across a panel of 48 tissues with different disease stages and histological grades. We also tested the effect of LPA on VEGF and VEGFR-2 expression and examined whether blocking VEGFR-2 by RNA interference (RNAi) affects LPA-induced EOC invasion.
RESULTS: We show that VEGF and VEGFR-2 expression correlates with cell invasiveness and VEGFR-2 expression in ovarian cancer tissues correlate with tumor grade. In addition, LPA, at 20 muM, significantly induced the expression of VEGF(121), VEGF(165), and VEGFR-2 in SKOV3 and DOV13 cells (P<0.05). VEGFR-2 small interference RNA (siRNA) transfection remarkably decreased LPA's invasion-promoting effect (P<0.001) in SKOV3 cells without significantly decreasing SKOV3 cells' basal invasiveness. In DOV13 cells, VEGFR-2 silencing significantly decreases both the basal level cell invasion and LPA's invasion promoting effect (P<0.001).
CONCLUSION: These results suggest that decreasing VEGFR-2 expression by RNAi may prove to be an effective method to reduce the metastatic potential of EOC cells exposed to elevated levels of LPA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19765808     DOI: 10.1016/j.ygyno.2009.08.019

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET.

Authors:  Iljung Lee; Kwang Yup Yoon; Choong Mo Kang; Xin Lin; Xiaoyuan Chen; Jung Young Kim; Sung-Min Kim; Eun Kyoung Ryu; Yearn Seong Choe
Journal:  Nucl Med Biol       Date:  2012-03-09       Impact factor: 2.408

2.  Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.

Authors:  E Alirahimi; A Ashkiyan; F Kazemi-Lomedasht; K Azadmanesh; M Hosseininejad-Chafi; M Habibi-Anbouhi; R Moazami; M Behdani
Journal:  Cancer Gene Ther       Date:  2016-12-16       Impact factor: 5.987

3.  Knockdown of the AKT3 (PKBγ), PI3KCA, and VEGFR2 genes by RNA interference suppresses glioblastoma multiforme T98G cells invasiveness in vitro.

Authors:  Monika Paul-Samojedny; Adam Pudełko; Renata Suchanek-Raif; Małgorzata Kowalczyk; Anna Fila-Daniłow; Paulina Borkowska; Jan Kowalski
Journal:  Tumour Biol       Date:  2014-12-14

Review 4.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

5.  Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.

Authors:  Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2012-09-22

6.  Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.

Authors:  Majid Momeny; Zahra Sabourinejad; Ghazaleh Zarrinrad; Farima Moghaddaskho; Haniyeh Eyvani; Hassan Yousefi; Shahab Mirshahvaladi; Ensieh M Poursani; Farinaz Barghi; Arash Poursheikhani; Leila Dardaei; Davood Bashash; Mahmoud Ghazi-Khansari; Seyyed M Tavangar; Ahmad R Dehpour; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

7.  CircASH2L Promotes Ovarian Cancer Tumorigenesis, Angiogenesis, and Lymphangiogenesis by Regulating the miR-665/VEGFA Axis as a Competing Endogenous RNA.

Authors:  Jinxin Chen; Xiaocen Li; Lu Yang; Mengmeng Li; Ye Zhang; Jingru Zhang
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 8.  The role of the VEGF-C/VEGFRs axis in tumor progression and therapy.

Authors:  Jui-Chieh Chen; Yi-Wen Chang; Chih-Chen Hong; Yang-Hao Yu; Jen-Liang Su
Journal:  Int J Mol Sci       Date:  2012-12-20       Impact factor: 5.923

9.  Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer.

Authors:  Limei Wang; Xiaoyan Liu; Hong Wang; Shuhe Wang
Journal:  Oncol Lett       Date:  2013-05-15       Impact factor: 2.967

10.  Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?

Authors:  Yu-Ling Li; Hua Zhao; Xiu-Bao Ren
Journal:  Cancer Biol Med       Date:  2016-06       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.